|
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
LHGDN |
Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with pancreatic cancer.
|
18095160 |
2008 |
|
Malignant neoplasm of breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among individuals homozygous for the fast metabolizing allele (ADH(3)1-1), a lifetime alcohol consumption of 15-30 g/day (approximately 1-2 drinks per day) increased breast cancer risk by 2-fold (OR=2.0, 95% CI=1.1-3.5).
|
16344274 |
2006 |
|
Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among individuals homozygous for the fast metabolizing allele (ADH(3)1-1), a lifetime alcohol consumption of 15-30 g/day (approximately 1-2 drinks per day) increased breast cancer risk by 2-fold (OR=2.0, 95% CI=1.1-3.5).
|
16344274 |
2006 |
|
Asthma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Among Puerto Ricans, several GSNOR SNPs and a haplotype in the 3'UTR were significantly associated with increased risk for asthma and lower bronchodilator responsiveness (P=0.04-0.007).
|
20335826 |
2010 |
|
Pancreatitis, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Area under the Receiver Operating Curve (ROC) curve for ADH III in AP and CP was 0.88 and 0.86 respectively.
|
29715134 |
2018 |
|
Sjogren-Larsson Syndrome
|
0.060 |
Biomarker
|
disease |
BEFREE |
Bezafibrate induces FALDH in human fibroblasts; implications for Sjögren-Larsson syndrome.
|
16837225 |
2006 |
|
Alcoholic Intoxication, Chronic
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
DTR analysis showed that ADH5 genotypes and diplotypes of ADH1A, ADH1B, ADH7, and ALDH2 were associated with AD in European Americans and/or African Americans.
|
16685648 |
2006 |
|
Alcoholic Intoxication, Chronic
|
0.330 |
Biomarker
|
disease |
PSYGENET |
DTR analysis showed that ADH5 genotypes and diplotypes of ADH1A, ADH1B, ADH7, and ALDH2 were associated with AD in European Americans and/or African Americans.
|
16685648 |
2006 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Especially, it caused the induction of growth-related transcriptional regulators (Jun, N-myc, Atf3) and the reduction of Rassf1 and two dehydrogenase genes (Dhrs1 and Adh5), which may be involved in the carcinogenesis of IDH1-mutated tumors.
|
21356389 |
2011 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Especially, it caused the induction of growth-related transcriptional regulators (Jun, N-myc, Atf3) and the reduction of Rassf1 and two dehydrogenase genes (Dhrs1 and Adh5), which may be involved in the carcinogenesis of IDH1-mutated tumors.
|
21356389 |
2011 |
|
Asthma
|
0.030 |
GeneticVariation
|
disease |
LHGDN |
Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma.
|
17543375 |
2007 |
|
Adrenoleukodystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Heavy drinkers with or without ALD significantly differed for the distribution of alleles of the cytochrome P4502E1 (CYP2E1) and alcohol-dehydrogenase-3 (ADH-3) genes.
|
11471570 |
2001 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Here we report that ALDH1L1 (FDH, a folate enzyme with tumor suppressor-like properties) inhibits cell motility.
|
20729910 |
2010 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we show that following left coronary artery ligation, mice with a targeted deletion of the S-nitrosoglutathione reductase gene (GSNOR(-/-)) have reduced myocardial infarct size, preserved ventricular systolic and diastolic function, and maintained tissue oxygenation.
|
19325130 |
2009 |
|
Malignant neoplasm of stomach
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
High expression of ADH 1A (class 1), α polypeptide (<i>ADH1A;</i> log-rank P=0.043; HR=0.79; 95% CI: 0.64-0.99), ADH 1B (class 1), β polypeptide (<i>ADH1B</i>; log-rank P=1.9×10<sup>-05</sup>; HR=0.65; 95% CI: 0.53-0.79) and ADH 5 (class III), χ polypeptide (<i>ADH5</i>; log-rank P=0.0011; HR=0.73; 95% CI: 0.6-0.88) resulted in a significantly decreased risk of mortality in all patients with GC compared with patients with low expression of those genes.
|
29552190 |
2018 |
|
Stomach Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
High expression of ADH 1A (class 1), α polypeptide (<i>ADH1A;</i> log-rank P=0.043; HR=0.79; 95% CI: 0.64-0.99), ADH 1B (class 1), β polypeptide (<i>ADH1B</i>; log-rank P=1.9×10<sup>-05</sup>; HR=0.65; 95% CI: 0.53-0.79) and ADH 5 (class III), χ polypeptide (<i>ADH5</i>; log-rank P=0.0011; HR=0.73; 95% CI: 0.6-0.88) resulted in a significantly decreased risk of mortality in all patients with GC compared with patients with low expression of those genes.
|
29552190 |
2018 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Human HCC development is often associated both with elevated expression of inducible nitric oxide synthase (iNOS) and with genetic deletion of the major denitrosylase S-nitrosoglutathione reductase (GSNOR/ADH5).
|
23440427 |
2013 |
|
Malignant neoplasm of oropharynx
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, the oropharyngeal cancer patients had excess frequencies of both GSTmu(-) (62%) and ADH(3)1/ADH(3)1 (43%) relative to the control group, but these excess frequencies were not statistically significant.
|
9050916 |
1997 |
|
Oropharyngeal Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, the oropharyngeal cancer patients had excess frequencies of both GSTmu(-) (62%) and ADH(3)1/ADH(3)1 (43%) relative to the control group, but these excess frequencies were not statistically significant.
|
9050916 |
1997 |
|
Asthma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In recent years, the therapeutic inhibition of GSNOR has been investigated to treat asthma, cystic fibrosis and interstitial lung disease (ILD).
|
28393572 |
2017 |
|
Lung Diseases, Interstitial
|
0.010 |
Biomarker
|
group |
BEFREE |
In recent years, the therapeutic inhibition of GSNOR has been investigated to treat asthma, cystic fibrosis and interstitial lung disease (ILD).
|
28393572 |
2017 |
|
Adenocarcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Individuals homozygous for ADH ( 3 ) (1-1) had a higher risk of each tumor type compared to individuals who had ADH ( 3 ) (2-2) or ADH ( 3 ) (1-2) genotype (OR = 1.7, 95% CI = 1.0-2.9 for esophageal and gastric cardia adenocarcinomas; OR = 1.7, 95% CI = 0.7-4.3 for esophageal squamous cell carcinoma; and OR = 2.8, 95% CI = 1.5-5.1 for non-cardia gastric cancer).
|
17665311 |
2007 |
|
Malignant neoplasm of stomach
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Individuals homozygous for ADH ( 3 ) (1-1) had a higher risk of each tumor type compared to individuals who had ADH ( 3 ) (2-2) or ADH ( 3 ) (1-2) genotype (OR = 1.7, 95% CI = 1.0-2.9 for esophageal and gastric cardia adenocarcinomas; OR = 1.7, 95% CI = 0.7-4.3 for esophageal squamous cell carcinoma; and OR = 2.8, 95% CI = 1.5-5.1 for non-cardia gastric cancer).
|
17665311 |
2007 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Individuals homozygous for ADH ( 3 ) (1-1) had a higher risk of each tumor type compared to individuals who had ADH ( 3 ) (2-2) or ADH ( 3 ) (1-2) genotype (OR = 1.7, 95% CI = 1.0-2.9 for esophageal and gastric cardia adenocarcinomas; OR = 1.7, 95% CI = 0.7-4.3 for esophageal squamous cell carcinoma; and OR = 2.8, 95% CI = 1.5-5.1 for non-cardia gastric cancer).
|
17665311 |
2007 |
|
Stomach Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Individuals homozygous for ADH ( 3 ) (1-1) had a higher risk of each tumor type compared to individuals who had ADH ( 3 ) (2-2) or ADH ( 3 ) (1-2) genotype (OR = 1.7, 95% CI = 1.0-2.9 for esophageal and gastric cardia adenocarcinomas; OR = 1.7, 95% CI = 0.7-4.3 for esophageal squamous cell carcinoma; and OR = 2.8, 95% CI = 1.5-5.1 for non-cardia gastric cancer).
|
17665311 |
2007 |